HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to dialysis.

Abstract
Alphacalcidol oral pulse therapy was given for secondary hyperparathyroidism to 22 children (mean age of 5.6 years) with renal insufficiency. At the beginning of the study, the glomerular filtration rate was < 50% of normal, serum intact parathyroid hormone (PTH) was > 100 ng/l and the serum phosphate and calcium concentrations were within the normal range. Alphacalcidol (0.5-3.0 micrograms) was given orally thrice weekly in the evening and adjusted according to PTH, ionized calcium and phosphate concentrations. Serum PTH (mean +/- SEM) decreased significantly from a pre-treatment level of 393 +/- 81 ng/l to 122 +/- 34 ng/l after 12 months, and stabilized at this level. Mean vitamin D metabolite concentrations were within the normal range. 1,25-Dihydroxyvitamin D did not increase during therapy, while PTH decreased. The estimated creatinine clearance remained almost unchanged (20 +/- 3 and 21 +/- 6 ml/min per 1.73 m2). Growth remained low normal (height standard deviation score -1.8 +/- 0.3 initially and -1.7 +/- 0.4 12 months later) and bone mineral density did not decrease. We concluded that feedback regulation of PTH with oral alphacalcidol pulse therapy is effective in the treatment of hyperparathyroidism in children with renal failure prior to dialysis.
AuthorsM Ala-Houhala, C Holmberg, K Rönnholm, A Paganus, J Laine, O Koskimies
JournalPediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 9 Issue 6 Pg. 737-41 (Dec 1995) ISSN: 0931-041X [Print] Germany
PMID8747116 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Hydroxycholecalciferols
  • Parathyroid Hormone
  • Phosphates
  • Calcium
  • alfacalcidol
Topics
  • Adolescent
  • Bone Density
  • Calcium (blood)
  • Child
  • Child, Preschool
  • Diet, Protein-Restricted
  • Female
  • Humans
  • Hydroxycholecalciferols (administration & dosage, therapeutic use)
  • Hyperparathyroidism, Secondary (drug therapy, etiology)
  • Infant
  • Kidney Failure, Chronic (complications, diet therapy, therapy)
  • Male
  • Parathyroid Hormone (blood)
  • Phosphates (blood)
  • Renal Dialysis
  • Uremia (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: